Dedicated to research, development and manufacturing of innovative cardiac medical devices, Shanghai Epygon Medical Technology Co., Ltd was jointly established by Shanghai Zuquan Investment Management Co., Ltd and Epygon S.A.S, a French enterprise, in April 2018.

Located in the Building 12-13 Landian Park of Shanghai International Medical Zone (SIMZ), Shanghai Pudong New Area, the Company is in the heart of a leading-edge Chinese medical cluster, with convenient geographical position, only 18 km from Shanghai Pudong Airport and 25km from Shanghai Hongqiao Airport, enjoying excellent infrastructure, intensive international exchanges and rich research and higher education resources.

Shanghai Epygon Medical Technology Co., Ltd endeavors to be as physiologic as possible for developing innovative cardiac products with an optimal fitting to anatomy and hemodynamics, in order to providing new opportunities to patents unfitted for conventional surgery.

The Chinese medical device market has achieved a fast development since 2010, with an average annual growth exceeding 20%, twice the growth of the drug market. According to China National Pharmaceutical Industry Information Center, it is expected to reach the volume of 600 billion RMB in 2019 and become the second largest market in the world after the United States in 2020.

Representing the second biggest sales after IVD in China, cardiovascular interventional devices offer important market potential and remarkable prospect in the context of inevitable aged tendency of population and high incidence of cardiovascular diseases.